Core Viewpoint - PreveCeutical Medical Inc. has filed an International (PCT) patent application for innovative methods to deliver CNS-active therapeutic agents, particularly targeting Parkinson's disease treatment [1][2]. Company Developments - The patent application, filed on February 5, 2026, is aimed at addressing challenges in treating neurological diseases, with a focus on Parkinson's disease, which affects over 10 to 12 million people globally [1][2]. - The company has developed a method to deliver dopamine directly to the brain, potentially eliminating the need for traditional treatments like L-dopa, which become ineffective as the disease progresses [4][6]. Industry Context - Parkinson's disease is the second most common neurodegenerative disorder after dementia, characterized by progressive symptoms that severely impact daily living and cognitive function [2]. - Current treatments primarily involve oral administration of L-dopa, which cannot cross the blood-brain barrier, leading to limitations in effective management as the disease advances [3][4]. Future Potential - PreveCeutical's approach could revolutionize the treatment landscape for Parkinson's disease and other CNS disorders by providing a direct replenishment of dopamine, offering a safer and more effective option for patients in advanced stages [4][6]. - The company is also exploring opportunities to address delivery challenges for a range of therapeutics restricted to peripheral administration for CNS conditions [5].